Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK

NCT02826811 is registered in ClinicalTrials.gov with University Hospital, Strasbourg, France as lead sponsor.

NCT NCT02826811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02826811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK
Lead sponsor
University Hospital, Strasbourg, France
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2016
Completion date
May 31, 2017
Enrollment
170 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft dysfunction